Ultragenyx Pharma Wins FDA’s First Drug Nod for Rare Metabolic Disorder

Ultragenyx Pharma Wins FDA’s First Drug Nod for Rare Metabolic Disorder

Source: 
Xconomy
snippet: 


Ultragenyx Pharmaceutical won FDA approval Tuesday for a therapy that treats a group of rare metabolic disorders that render the body unable to convert a certain type of fat—such as those found in olive oil, fish, and nuts—into energy.